Reply to the letter to the Editor "Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts".

Simon, Nicolas; Alvarez, Jean Claude

Simon, Nicolas; Alvarez, Jean Claude.

Simon N; APHM, INSERM, IRD, SESSTIM, Hop Sainte Marguerite, Service de Pharmacologie Clinique, CAP-TV, Aix-Marseille University, Marseille, France.
Alvarez JC; Département de Pharmacologie-Toxicologie, Hôpitaux Universitaires Paris-Ile de France-Ouest, APHP, Hôpital Raymond Poincaré, FHU Sepsis, MasSpecLab, Plateforme de spectrométrie de masse, Inserm U-1173, Université Paris Saclay (Versailles Saint Quentin-en-Yvelines), 92380, Garches, France. jean-claude.alvarez@aphp.fr.

Eur J Clin Pharmacol ; 77(5): 793-794, 2021 05.

Article in English | MEDLINE | ID: covidwho-947027

Subject(s)

COVID-19 Drug Treatment; Ritonavir; Antiviral Agents/therapeutic use; Humans; Lopinavir; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Ritonavir / COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study Limits: Humans Language: English Journal: Eur J Clin Pharmacol Year: 2021 Document Type: Article Affiliation country: S00228-020-03056-y

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google